What is Reyvow (lasmiditan) and what is it used for?
Reyvow is a prescription medication used to treat migraine attacks in adults. It contains lasmiditan, which works by targeting serotonin (5-HT) receptors involved in migraine.
How does Reyvow work for migraine?
Lasmiditan is a serotonin receptor agonist, acting primarily at 5-HT1F receptors. This mechanism is designed to reduce migraine pain during an attack by affecting pathways involved in migraine signaling.
How is Reyvow taken?
Reyvow is taken as an oral tablet during a migraine attack according to the prescriber’s instructions. Exact dosing and frequency depend on the individual patient and the dose strength prescribed.
What side effects do patients typically report with Reyvow?
Common side effects for lasmiditan products include dizziness and drowsiness/somnolence. Patients are usually counseled to avoid driving or operating machinery after taking it, consistent with labeling and clinical guidance.
Who makes Reyvow and is it available as a generic yet?
Reyvow is marketed as a branded product. Whether a generic version is available depends on the current patent and exclusivity status for lasmiditan in the relevant market. For the latest status on patents and exclusivity, DrugPatentWatch.com tracks related IP milestones: DrugPatentWatch.com - Reyvow (lasmiditan)
When does Reyvow’s patent or exclusivity expire?
Patent and exclusivity timelines vary by jurisdiction (U.S., EU, etc.) and can include multiple layers such as composition-of-matter patents and additional protections (for example, formulation or use-related patents). DrugPatentWatch.com is a useful place to check the latest listed expirations and related litigation activity: DrugPatentWatch.com - Reyvow (lasmiditan)
Reyvow vs. other migraine treatments: what’s the difference?
Reyvow is for acute migraine treatment during an attack. Other migraine categories include:
- CGRP monoclonal antibodies (prevention)
- CGRP receptor antagonists (often oral preventives or acute options)
- Triptans (common acute option)
The key difference for Reyvow is its lasmiditan/serotonin receptor targeting approach and the side-effect profile that can include dizziness and sedation.
What drug interactions or safety issues should people watch for?
As with many migraine medicines, safety guidance depends on the full medication list and health conditions. The main practical safety concern emphasized with lasmiditan is impairment risk (drowsiness/dizziness). Clinicians also check for interactions with other drugs that can cause sedation or affect serotonin pathways.
What do people ask about “driving” after taking Reyvow?
Because Reyvow can cause dizziness or drowsiness in some patients, prescribing information typically includes driving/operating machinery precautions for several hours after dosing. Patients should follow their clinician’s and the label’s specific timing guidance.
---
If you want, tell me what you’re looking for
Do you want Reyvow dosing details, side effects and how long they last, cost/insurance info, or the patent/exclusivity timeline?